Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

Brilacidin, a mimetic of host defense peptides (HDPs), is currently in Phase 2 clinical trial as an antibiotic drug candidate. A recent study reported that brilacidin has antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) by inactivating the virus. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yanmei, Jo, Hyunil, DeGrado, William F., Wang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930451/
https://www.ncbi.nlm.nih.gov/pubmed/35080027
http://dx.doi.org/10.1002/jmv.27616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930451/
https://www.ncbi.nlm.nih.gov/pubmed/35080027
http://dx.doi.org/10.1002/jmv.27616

Ejemplares similares